Microencapsulation of drugs into preformed polymers is commonly achieved through solvent 10 evaporation techniques or spray drying. We compared these encapsulation methods in terms of 11 controlled drug release properties of the prepared microparticles and investigated the underlying 12 mechanisms responsible for the "burst release" effect. Using two different pH-responsive polymers 13 with a dissolution threshold of pH 6 (Eudragit L100 and AQOAT AS-MG), hydrocortisone, a model 14 hydrophobic drug, was incorporated into microparticles below and above its solubility within the 15 polymer matrix. Although, spray drying is an attractive approach due to rapid particle production 16 and relatively low solvent waste, the oil-in-oil microencapsulation method is superior in terms of 17 controlled drug release properties from the microparticles. Slow solvent evaporation during the oil-18 in-oil emulsification process allows adequate time for drug and polymer redistribution in the 19 microparticles and reduces uncontrolled drug burst release. Electron microscopy showed that this 20 slower manufacturing procedure generated non-porous particles whereas thermal analysis and X-ray 21 diffractometry showed that drug loading above the solubility limit of the drug in the polymer 22 generated excess crystalline drug on the surface of the particles. Raman spectral mapping illustrated 23 that drug was homogeneously distributed as a solid solution in the particles when loaded below 24 saturation in the polymer with consequently minimal burst release. 25 26
Introduction
29 Polymeric microparticles are increasingly used for controlled drug delivery. Preparation of these 30 microparticles from pre-formed polymers is based on modifications of three basic methods; solvent 31 extraction/evaporation, phase separation (coacervation) and spray-drying [1] . The emulsification 32 solvent evaporation approach is a simple and widely applied technique, extensively studied for the 33 preparation of polylactic acid (PLA) and poly(lactic-co-glycolic) acid (PLGA) microparticles [2, 3] . 34
However, this technique uses relatively large amounts of solvents and results in a suspension of 35 microparticles in the external phase [4] [5] [6] . To acquire a dry powder further processing, such as 36 filtration or lyophilisation, is needed. Another frequent problem encountered using conventional 37 emulsification methods is drug crystallisation in the external continuous phase [6] . This problem was 38 overcome in the case of progesterone-loaded polylactide microspheres using a spray drying method, 39 hot air being the external phase [7] . 40
With regards to controlled-release properties, one of the difficulties often reported for polymeric 41 microparticles is an initial high drug release from the polymer matrix, known as a "burst release 42 effect" [5, [8] [9] [10] [11] [12] [13] . In an attempt to explain this phenomenon, a number of theories have been suggested. 43 Wang et al. (2002) related drug release to the density of the produced microparticles suggesting that 44 denser particles result in lower release rates [11] . Other authors attributed the burst release to high 45 residual solvent, reduced glass transition temperature, surface drug enrichment or insufficient 46 encapsulation [13] [14] [15] [16] . In fact, it is well established that the distribution of drugs in delivery systems 47 influences the release characteristics [15] . However, this is often hard to quantify in-situ and detailed 48 investigations into the mechanisms responsible for the burst release effect in various 49 microencapsulation methods have not been reported. 50
This work evaluates microencapsulation methods in terms of optimal controlled-release 51 characteristics and uses various analytical techniques to investigate the possible underlying 52 mechanisms causing burst-or controlled-release properties. Two different pH-responsive polymers 53 with a dissolution threshold of pH 6 (Eudragit L100 and AQOAT AS-MG) were used to encapsulate 54 hydrocortisone, a model hydrophobic drug, into microparticles below and above its solubility within 55 the polymer matrix. Varying the drug loading above and below the solubility within the polymer 56 tests whether drug encapsulation using spray drying is only marginally dependent on the drug's 57 affinities to the solvent and polymer used [7] . Raman microscopy was then used to investigate the 58 spatial distribution of the drug within the produced microparticles which was related to 59 experimental release profiles. Unlike previous studies which develop pH-responsive microparticles 60 intended for gastro-intestinal drug delivery, the goal of this work was to develop controlled delivery 61 emulsified into 100 ml liquid paraffin (oil 2 ) containing 1% w/w of sorbitan sesquioleate as an 93 emulsifying agent [19] . 94
For both techniques, the emulsion was obtained by stirring (4 cm four-blade propeller) at 1200 rpm 95 (IKA ® Laboratechnik). Solvent removal was achieved by continuous stirring of the emulsion droplets 96 at 1200 rpm overnight at room temperature to allow solvent evaporation. The solidified 97 microparticles were then recovered by vacuum filtration (through Whatman filter paper, 0.45 µm 98 pore size), washed with 200 ml of water in the case of the oil-in-water emulsification or with three 99 portions of 25ml n-hexane after the oil-in-oil microencapsulation process. This was followed by 100 vacuum drying for 6 hrs at room temperature. 2.5%, 10% and 25% w/w hydrocortisone-loaded 101 microparticles were obtained by incorporating the appropriate drug amount to the initial polymeric 102 solutions. 103 Where, W total is the total solids weight used in the initial polymeric solution and W recovered is the 108 weight of recovered microparticles. To calculate drug encapsulation efficiency, amounts of dry 109 powder samples equivalent to 20 µg/ml theoretical hydrocortisone loading were dissolved in 110 ethanol for Eudragit L100 microparticles and in pH7 phosphate buffer for AQOAT AS-MG (as this 111 polymer is insoluble in ethanol). The amount of hydrocortisone encapsulated was determined by UV 112 spectrophotometry (Jasco V-530 UV-VIS spectrophotometer) at 242 nm (ethanol) or 248 nm (pH 7 113 phosphate buffer) against calibration curves. The encapsulation efficiency (EE) was calculated as: 114 
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Density
125
Bulk density (bρ) was measured by filling the dry powder into a 2 ml graduated syringe whose 126 bottom was sealed with Parafilm ™ [20, 21] . The weight and volume occupied by the powder was 127 recorded to calculate bρ. The tap density (tρ) of the powders was then evaluated by tapping the 128 syringe onto a level surface at a height of about 2 cm [20] , until no change in volume was observed. 129
The resultant volume was then recorded to calculate tρ. Each measurement was performed in 130 triplicate. 131
Thermo-gravimetric Analysis (TGA)
132 Thermo-gravimetric analysis assessed the residual solvent within the prepared microparticles. These 133 investigations were performed in a Q50 TA instrument (TA Instruments Ltd, UK) equipped with TA 134 universal analysis software. Samples of about 10 mg were heated from 30 to 200°C at 20°C /minute 135 under a nitrogen purge of 50 ml/min using a platinum pan. 136
Differential scanning calorimetry (DSC)
137 Thermal behaviour of polymers, drug, drug free microparticles and drug-loaded microparticles was 138 analysed using differential scanning calorimetry (Q2000 TA instruments) equipped with TA universal 139 analysis software. The apparatus was calibrated with indium prior to analysis. Approximately 4 mg 140 samples were accurately weighed into standard aluminium pans, which were then crimped and 141 heated from 30 to 150°C at 10°C/minute with a 30 min isothermal hold at 150°C to remove any 142 excess moisture. The samples were then cooled to 30°C and heated to 250°C at 10°C /minute under 143 a nitrogen purge of 20ml/min. All samples were tested in triplicate. 144
X-ray powder diffraction (XRPD) measurements
145 X-ray powder diffraction patterns of the starting materials (hydrocortisone and Eudragit L100) and 146 microparticles were obtained using a Bruker D8 Advance diffractometer (Bruker, Germany), using Cu 147 Kα radiation (λ= 1.5406 Å). Samples were scanned from 5 to 45° 2θ, with a step size of 0.017° and a 148 count time of 3 seconds per step. Samples were rotated at 30 rpm during analyses. The generator 149 was set to 40 keV and 40 mA. 150
Raman microscopy
151 Raman spectra were recorded using a dispersive Renishaw inVia Raman microscope coupled with a 152 6 used for optical imaging and spectral acquisition. The collected radiation was directed through a 154 notch filter that removes the Rayleigh photons, then through a confocal hole and the entrance slit 155 onto a grating monochromator (2400 groove/mm) that disperses the light before it reaches the 156 charge-coupled device (CCD) detector. The spectrograph was set to provide a spectral range of 100-157 2000 cm -1 . 158
Depth profiling of the oil-in-oil generated microparticles was acquired at a step of 2 µm for the 25% 159 hydrocortisone-loaded microparticles and a step of 0.8 µm for 10% and 2.5% w/w loaded-160 microparticles. Spectrum acquisition times were typically 180s. Spectra were collected to a total 161 depth of 15.20 µm, for the 2.5% and 10% w/w hydrocortisone-loaded microparticles, and 38 µm for 162 25% hydrocortisone-containing microparticles due to their larger particle diameters. In all cases, a 163 total of 20 spectra were acquired starting from the microparticle's surface. 164 The reported aqueous solubility of hydrocortisone is 0.28 mg/ml [18, 22] . Therefore, amounts of drug-169 containing microparticles equivalent to 0.02 mg/ml hydrocortisone on complete dissolution were 170 used, ensuring sink conditions (C<0.1 C s ). The powders were first tested in 500 ml of 0.1M pH 5 171 phosphate buffer for two hours, after which the pH was increased to 7 by the addition of 100 ml 172 0.29M NaOH, and testing then continued for a further two hours. Samples (1 ml) were withdrawn 173 periodically, passed through a 0.45 µm membrane filter (Millipore ® ) and assayed by UV 174 spectrophotometery at 248 nm, a wavelength at which no interference from the polymers was 175 observed. 176
In vitro dissolution testing
Statistical analysis
177 Differences in tap density measurements and maximum drug release between Eudragit L100 178 microparticles obtained from the two methods (spray drying and solvent evaporation) and 179 containing different drug-loadings were assessed using one way analysis of variance, (Genstat; 180 version 12); in all cases p<0.05 denoted significance. 181
3 Results and discussion 182 Unlike the solvent evaporation technique, encapsulation using spray drying is thought to be only 183 slightly dependent on the drug's compatibility with the solvent and polymer used [7] . In this study, 184 the effect of drug:polymer compatibility on hydrocortisone release from the prepared microparticles 185 was explored by incorporating the drug at levels below and above its solubility limit within the 186 polymer matrices. The solubility of hydrocortisone in Eudragit L100 and AQOAT AS-MG was found 187 through microscopic examination of polymer films [23] . A high solubility of the drug in the polymer 188 matrix is indicative of high drug-polymer compatibility [6, 23] and results in better incorporation of the 189 drug within the prepared microparticles. Hydrocortisone was found to be more soluble (13-14% 190 w/w) in Eudragit L100 films [24] compared to AQOAT AS-MG (9-10% w/w; Figure 1 ). 191
INSERT Figure 1 192
Various other parameters including the physicochemical properties of both drug and polymer need 193 to be considered for successful encapsulation of drugs into polymeric microparticles. The model 194 drug used, hydrocortisone, has a reported water solubility of 0.28 mg/ml [16] , and we previously 195 reported its solubility in ethanol to be 11.4±0.33 mg/ml [24] . These solubility's dictate the extent of 196 drug diffusion to the surface of the microparticles during the preparation process and ultimately 197 affect drug release. 198 We previously reported the potential use of spray drying to prepare pH-responsive Eudragit L100 201 microparticles [24] . The method was optimised in terms of drug release, taking into account the effect 202 of different solvent systems and various polymer concentrations. Using Eudragit L100 as a pH-203 responsive polymer, it was found that a polymer content of 2% w/w and a solvent system of 1:1 w/w 204 ethanol/water led to the lowest drug release at pH 5, a pH at which the polymer is not soluble. Using 205 these optimised conditions, the effect of varying the drug loading (2.5% and 25% w/w) on the 206 release profile was investigated [24] . Here, we also report the effect of 10% w/w hydrocortisone-207 loading ( Table 1) . AQOAT AS-MG microparticles were also generated using the same conditions to 208 explore the methods' transferability to other polymers (Table 1) . Encapsulation efficiency was high, 209
Preparation of pH-responsive microparticles
with more that 88% of the drug incorporated in all cases. Morphological characteristics of Eudragit 210 L100 and AQOAT AS-MG microparticles containing different hydrocortisone loadings were examined 211 with SEM imaging as shown in Figure 2 . The rough morphology of these microparticles is thought to 212 result from polymer phase separation at the surface of the drying droplets [24] . 213
INSERT Table 1 214 INSERT Figure 2 215
Powders prepared from AQOAT AS-MG tended to aggregate. The presence of aggregates increases 216 the voids within the powder bed and results in relatively low tap densities compared with Eudragit 217 L100 microparticles [24] (Table 1) . Further investigation of the pH-responsiveness of these spray dried 218 microparticles, from pH 5 to 7, demonstrated that AQOAT AS-MG particles dissolve at a lower pH 219 than expected, between pH 5.3 and 5.4 (data not shown). Similar observations were reported by 220
Friesen et al who found AQOAT AS-MG soluble above pH 5.2 [25] . In contrast, Eudragit L100 221 microparticles dissolved at pH 5.8 to 5.9, close to the reported polymer solubility threshold of pH 6 222 [24] . Differential scanning calorimetry did not show any changes between the polymer microparticles 223 and the initial AQOAT AS-MG powder (data not shown). The discrepancy in pH-responsiveness 224 between the manufacturer information and experimental results for AQOAT AS-MG might be a 225 result of differences in testing methodologies; the manufacturer's information is based on 226 disintegration testing of 1 cm 2 polymeric films which may dissolve more slowly than the 227 microparticles [26] . 228
Due to the relatively high drug burst release observed previously with spray-dried Eudragit L100 229 microparticles at pH 5 and 1.2 [24] , pHs at which the polymer is not soluble, an alternative 230 microencapsulation technique, namely, the solvent-evaporation method, was investigated. 231
Oil-in-water emulsification/solvent evaporation technique
232
In the oil in water emulsification process, the drug and polymer are first dissolved in a water-233 immiscible solvent, usually dichloromethane (DCM), and the resulting organic phase is emulsified 234 into an aqueous phase containing an appropriate emulsifier. The organic solvent can then be 235 removed by evaporation or extraction. The method has been used to prepare Eudragit-based 236 systems, for the sustained release grades RL and RS [27, 28] , which are neutral copolymers of poly 237 (ethylacrylate, methyl methacrylate) and trimethyl aminoethyl methacrylate chloride [27] . pH-238 responsive particles have also been successfully prepared using Eudragit P-4135F [29] [30] [31] ; Eudragit P-239 4135F is synthesised by the co-polymerisation of methacrylic acid, methyl methacrylate and methyl 240 acrylate [31] and exhibits a dissolution threshold of pH 7.2 [31] . 241
The above Eudragit grades are all soluble in DCM, which is advantageous as it facilitates the 242 emulsification of the polymer solution. Moreover, the limited solubility of DCM in water prevents 243 drug loss to the external aqueous phase which can occur with solvent diffusion. However, Eudragit 244 L100 is not soluble in DCM whereas AQOAT AS-MG is only partially soluble (swellable) [32] . Therefore, 245 a mixed solvent of 7:3 v/v DCM/ethanol was used to solubilise the polymers in the initial organic 246 phase [33] [34] [35] [36] ; the ethanol content was minimised to limit drug diffusion into the aqueous phase. 247
Using the DCM/ethanol cosolvent system, microparticles were successfully prepared using a 10% 248 w/v AQOAT AS-MG organic solution ( Figure 3 ). The hollow nature of these microparticles is 249 attributed to rapid ethanol diffusion followed by polymer precipitation [35] . The rate of solvent 250 diffusion during the initial stage of microparticle preparation is determined by its water solubility. 251
The aqueous solubility of DCM at 25⁰C is 1.85% [2, 11] whereas ethanol is completely miscible with 252 water. The partial solubility of AQOAT AS-MG in DCM means that the polymer shell formed at the 253 interface of the emulsification droplets is non-rigid. This allows for DCM evaporation through 254 eruptions in the polymeric shell. The net result is the formation of spherical intact microparticles 255 with a porous surface upon complete shell solidification (e.g. Figure 3 , D). 256
INSERT Figure 3 257
These morphological observations are consistent with tap density measurements of AQOAT AS-MG 258 microparticles (Table 2) , which are considerably lower than those calculated for the spray dried 259 powders (Table 1) and are attributed to the hollow nature of the particles. However, hydrocortisone 260 encapsulation into AQOAT AS-MG microparticles resulted in relatively low encapsulation efficiencies 261 (Table 2) Eudragit L100-55 [6] . 264
INSERT Table 2  265 Although hydrocortisone is a hydrophobic drug, it exhibits an appreciable solubility in aqueous 266 media of 0.28 mg/ml [16] . The diffusion of ethanol into the external aqueous phase during the 267 emulsification process leads to drug leaching and increased hydrocortisone solubility in the external 268 aqueous phase. This phenomenon may explain the low encapsulation efficiency measured and the 269 appearance of drug crystals in the external aqueous phase at 25% w/w theoretical drug loading 270 (Figure 3, C). Microparticles prepared at 2.5% w/w drug loading show similar morphological 271 characteristics to the drug-free microparticles with no visual evidence of drug crystallisation ( Figure  272 3, B). Nonetheless, the encapsulation efficiency of the drug was low despite the fact that it was 273 incorporated at a level well below its solubility limit within the polymer. 274
In contrast, at 10% w/w polymer concentration, sticky Eudragit L100 droplets were produced during 275 the early stages of the oil-in-water emulsification process leading to the formation of elongated 276 polymeric structures (data not shown). In an attempt to overcome this problem, a reduced polymer 277 concentration was used to decrease polymer-polymer interactions in the initial polymeric organic 278 solution which, in turn, reduces the polymer's tendency for precipitation and enables polymer 279 emulsification into the external aqueous phase. Nonetheless, the emulsified droplets generated in 280 the early stages of particle formation tended to collapse during the solvent evaporation step ( Figure  281 3, E), possibly due to the brittle nature of the Eudragit L100 shell that forms at the interface of the 282 droplets. The glass transition temperature of Eudragit L100 was reported to be about 160⁰C with a 283 corresponding minimum film formation temperature (MFT) of 85⁰C [36] . Similarly to AQOAT AS-MG, 284 the hollow nature of Eudragit L100 microparticles is attributed to rapid ethanol diffusion, polymer 285 precipitation and subsequent shell formation. 286
Oil-in-oil emulsification/solvent evaporation technique 287
An oil-in-oil emulsification process was adopted to circumvent the problem of drug leakage into the 288 external phase. Kendall et al have recently developed a reproducible oil-in-oil microencapsulation 289 method for fabricating Eudragit L100 microparticles intended for gastrointestinal delivery [19] . The 290 method uses liquid paraffin, a non-solvent for both drug and polymer, as the external oil phase. 291
Despite the fact that the use of DCM (ICH class 2) was avoided and ethanol (ICH class 1) was chosen 292 to solubilise the polymer in the internal oil phase, the utilisation of hexane (ICH class 2) for external 293 oil phase removal is inevitable. 294
Drug-free Eudragit L100 microparticles prepared from a 10 % w/v polymeric solution using the oil-in-295 oil emulsification process have a smooth surface and are less polydisperse than microparticles 296 produced from the spray drying method ( Figure 4 ) with no observed surface porosity. The 297 solubilisation of 2.5% and 10% w/w hydrocortisone in the initial polymeric solution led to the 298 formation of spherical microparticles with similar morphological characteristics. At 25% w/w 299 theoretical drug loading, hydrocortisone was not fully soluble in the initial polymeric solution due to 300 its limited solubility in ethanol. Therefore, the non-solubilised drug crystals are incorporated into 301 relatively large microparticles (about 150 µm diameter compared with 30 µm diameter for drug-302 free, 2.5 and 10% drug-loaded microparticles) ( Figure 4 ). The presence of drug crystals at a relatively 303 high theoretical loading might have increased the viscosity of the initial polymeric solution. A more 304 viscous phase will require larger shear stress (stirring in this case) to break the emulsion droplets 305 into smaller sizes. 306
INSERT Figure 4 307
Yield, encapsulation efficiency and tap density results obtained from the emulsification of 10% w/v 308 polymeric solutions into liquid paraffin are presented in Table 3 . The encapsulation efficiencies 309 obtained for hydrocortisone are relatively high, comparable to those calculated for the spray dried 310 powders ( Table 1) . The lower encapsulation efficiency at 25% w/w theoretical drug loading can be 311 explained by the loss of uncoated drug crystals into the external oil phase. The high tap density 312 measurements obtained for the oil in oil microparticles suggest that they are solid. However, the oil-313 in-oil generated Eudragit L100 microparticles with 25% hydrocortisone-loading presents a low tap 314 density due to the presence of crystals within the microparticles which might have disturbed their 315 internal structure and led to pore formation (Figure 4, D) . 316
INSERT Table 3  317 The relatively high polymer concentration (10 % w/v), used in the internal oily phase, increased 318 polymer viscosity and caused rapid droplet solidification [2] . The rapid solidification of microparticles 319 is advantageous in achieving high drug encapsulation efficiency as it hinders drug migration to the 320 particles' surface [2] . In fact, a 1% w/v Eudragit L100 concentration led to inefficient hydrocortisone 321 encapsulation with apparent drug crystals in the external phase and on the surface of the dried 322 microparticles (data not shown). In this case, the low polymer viscosity and slow droplet 323 solidification allowed more time for drug loss through diffusion. 324
The transferability of the oil-in-oil microencapsulation method to different grades of Eudragit; L100, 325 S100 and L55, has been reported by Kendal et al. [19] . Nonetheless, its applicability to structurally 326 non-related polymers has not been investigated. Here, the oil-in-oil emulsification method was used 327 to prepare AQOAT AS-MG microparticles but the initial oil phase was substituted by a 7:3 v/v 328 DCM/ethanol co-solvent system to allow for AQOAT solubilisation. SEM images of the obtained 329 microparticles show similar morphological characteristics to Eudragit L100 particles but with a 330 rougher surface topography (Figure 4 , E and F). 331
Unlike the oil-in-water emulsification method, the microparticles obtained from the oil-in-oil 332 microencapsulation process appear to be solid. This can be attributed to the relatively slow "good 333 solvent" (ethanol) removal rate. This allows time for polymer redistribution within the drying 334 droplets and results in the formation of solid microparticles. Even when a mixed solvent of 335 DCM/ethanol is used, as for AQOAT AS-MG, the morphology of the particles obtained is similar to 336 that for Eudragit using ethanol alone. 337
Drug release 338
From the different microencapsulation techniques tested, spray drying and the oil-in-oil 339 microencapsulation method resulted in the successful formation of microparticles with efficient drug 340 encapsulation. Dissolution data of these powders are in Figure 5 , showing stepped dissolution of 341 microparticles below and above the pH solubility of the polymer. Although the size of the 342 microparticles can influence the rate of drug release in the initial stages, here we compare total drug 343 release after 2 hours at pH 5, when a plateau is reached. Total drug release at this stage is more 344 likely to be due to other factors such as particles porosity or drug distribution. In fact, a study that 345 investigated the release 5-fluorouracil-loaded PLGA-based microparticles has showed that 346 underlying drug release mechanisms were independent of the microparticle size [37] . Although the 347 different size fractions released the drug at different rates initially, they all reached the same level of 348 relative drug release after 21 days [37] . 349
INSERT Figure 5 350
With both preparation methods, Eudragit L100 microparticles showed better controlled release 351
properties than AQOAT AS-MG microparticles, i.e. lower relative drug release after 2 hours at pH 5. (Figure 5, B ). This suggests that the 358 remaining 10% of undissolved drug crystals is incorporated deeper into the polymer matrix. In 359 contrast, regardless of the drug loading level, the spray dried powders showed a high burst release 360 effect at pH 5, a pH at which the polymer is not soluble (Figure 5, A) . 361
These variations in drug release can be attributed to differences in microparticle formation during 362 manufacture. The burst release observed from the spray-dried microparticles implies that they are 363 porous; the presence of pores within microparticles leads to rapid water penetration inside the 364 particles and subsequent rapid diffusion of the encapsulated drug. The process of pore formation 365 during spray drying arises from phase separation during the encapsulation process and subsequent 366 drug partitioning between polymer-poor and rich regions within the drying droplet [24] . This 367 phenomenon results in some drug entrapped within the polymer-poor region which dries to form 368 pores or less supported structures [11] . 369 Interestingly, the spray dried microparticles containing hydrocortisone below the solubility limit 370 within the polymer (2.5 and 10% w/w) provided lower burst release than at 25% w/w loading ( Figure  371 5, A). Spray drying below the solubility limit of the drug might lead to higher drug content in the 372 polymer-rich regions of the dried particles and possibly better controlled release properties. 373
Nonetheless, at 2.5% and 10% w/w hydrocortisone loading, the burst release at pH 5 was only 374 reduced by about 10% at 2 hours compared to that when the drug exceeded its solubility at 25% 375 w/w load. This implies that either; a) drug partitioning to polymer-poor regions was still 376 predominant or b) drug enrichment at the surface was also accounting for the drug burst release. As 377 the evaporating droplet shrinks, its receding droplet surface leads to increased solute concentration 378 at the surface and subsequent diffusional flux to the centre [38] . During the spray drying process, high 379 solvent evaporation rates can lead to rapid droplet shrinking which does not allow time for drug 380 redistribution and results in surface drug enrichment [14] . 381
On the other hand, with the oil-in-oil microencapsulation process, solvent evaporation occurs more 382 slowly as the emulsified droplets are stirred overnight at room temperature to allow for complete 383 solvent evaporation. The relatively long evaporation time during the oil-in-oil microencapsulation 384 process, compared with the fast solvent evaporation during spray drying, allows adequate time for 385 both drug and polymer redistribution and diffusion to the centre of the emulsified droplets which 386 may result in better controlled release characteristics. Moreover, the long evaporation time is less 387 likely to produce porous microparticles. In comparison to Eudragit L100 microparticles, 388 hydrocortisone-loaded AQOAT AS-MG particles resulted in a significantly higher drug release at pH 5 389 ( Figure 5 , C & D) despite the fact that the drug was incorporated at 2.5% w/w, a level well below the 390 solubility limit of hydrocortisone within the polymer matrix. This can be attributed to differences in 391 the internal phase solvent system. The use of a DCM/ethanol co-solvent system may lead to a more 392 porous structure due to the relatively fast evaporation of DCM and might explain the lower tap 393 density measurements obtained for AQOAT AS-MG microparticles ( Table 2) . 394
It is notable that the rate of drug release from the oil in oil microparticles at pH 7 ( Figure 5 , B, post 395 120 mins) increases with drug loading. This effect may reflect drug distribution within the polymer 396 matrix; the more drug available at or near the surface of the particle the more rapid is the initial 397 release since less polymer is available to hinder drug diffusion. Using the same oil in oil 398 microencapsulation method, Nilkumhang et al. investigated partitioning of fluorescent dyes 399 between the internal (ethanol) and external (liquid paraffin) phases and found a correlation between 400 the partition coefficient and molecular distribution within the prepared microparticles [39] . However, 401 in this study, the same drug is used and the partition coefficient between ethanol and liquid paraffin 402 is therefore constant. 403 Wang and Wang (2002) suggested that the density of the produced microparticles could profoundly 406 influence drug release since increased particulate density can restrict the diffusion of the drug from 407 the microparticles [11] . Tap density measurements can offer insight into this phenomenon; assuming 408 perfect packing of the tapped powder and a monodisperse size distribution, tap density values are 409 approximately a 21% underestimate of particle density [40] . Although this method may not fully 410 discriminate between subtle structural differences due to possible electrostatic interactions, 411 especially when dealing with small particles, it has previously been useful employed to study 412 microparticles [20] and the data supports that from our SEM imaging and Raman microscopy 413
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investigations. 414
Tap density measurements of the spray dried and oil-in-oil microparticles are reported in Table 1  415 and 3 respectively. For both polymers loaded with drug below the solubility limit (2.5% and 10% 416 w/w), the oil-in-oil microparticles displayed significantly higher tap densities than the spray dried 417 particles. This correlates with in-vitro release testing as the more dense oil-in-oil Eudragit particles 418 showed negligible drug release at pH 5 ( Figure 5, B ) compared with the less dense spray dried 419 particles of the same polymer ( Figure 5, A) . Likewise, the oil-in-oil generated AQOAT particles gave 420 lower burst release at pH 5 than the equivalent spray dried material. Thus, for both polymers, 421 significant burst release correlated with lower tap densities. 422
In contrast, microparticles prepared from the oil/oil method at 25% w/w drug-loading showed a 423 significantly lower tap density measurement than other Eudragit L100 microparticles (Table 3 ) 424 suggesting a higher level of intraparticulate voids (p<0.05). This increased porosity might be due to 425 the presence of drug crystals in the initial polymeric solution which might have disturbed the flow of 426 the polymer within the emulsification droplets leading to the formation of pores. Moreover, drug 427 crystals are more likely to accumulate at the polymer/liquid paraffin interface during droplet drying 428 and surface recession. Eudragit S100 microparticles containing 50% and 66.7% w/w prednisolone 429 were hollow and showed an extensive amount of crystalline drug on the surface [41] . As expected, 430 these morphological changes were also attributed to a high burst release [41] . Similarly, Yadav et al. 431 (2009) [42] showed that increased intraparticle porosity of carbamazepine in Eudragit RSPO was due 432 to low polymer deposition in the empty spaces between the agglomerated microcrystals. Increased 433 drug deposition at the surface of our microparticles coupled with increased intraparticulate porosity 434 explains the relatively high burst release of hydrocortisone from 25% w/w drug-loaded 435 microparticles produced from the oil in oil emulsification method (Figure 5, B) . the polymer, leading to accelerated water uptake and greater drug diffusion from the microparticles 440 [13] . The residual solvent in the microparticles prepared from the oil-in-oil and spray drying methods 441 at different drug loadings was determined using thermo-gravimetric analysis (Table 4) . No significant 442 differences (P>0.05) were seen between the two methods of manufacture or between various drug 443 loadings, showing that, for these particles, residual solvent effects were not responsible for burst 444 effects. It should be noted that residual paraffin from the oil in oil method is not detected by this 445 technique. However, paraffin is a hydrophobic non-solvent for the polymer and therefore is not 446 expected to increase water uptake or influence drug release. 447 
INSERT
449
Differential scanning calorimetry and X-ray analysis of Eudragit L100, hydrocortisone, drug-free 450 microparticles and hydrocortisone-loaded microparticles were used to identify changes in drug form 451 that might have occurred during the encapsulation process ( Figures 6 and 7) . Drug encapsulation 452 within microparticles depends on its initial state in the polymeric solution and on the preparation 453 process [43] . Differential scanning calorimetry of untreated Eudragit L100 shows a broad phase 454 transition between 180 and 235˚C ( Figure 6 ). The nature of this phase transition is still unclear, but 455 dissociation of inter-molecular hydrogen bonds and anhydride formation has been suggested [44] . 456
The DSC curve of hydrocortisone powder show an endothermic melting peak at 222±0.7˚C ( Figure 6 Drug-free, 2.5% and 10% w/w hydrocortisone-loaded Eudragit L100 microparticles prepared from 461 the oil-in-oil microencapsulation method did not show any additional phase transitions to those 462 already observed in the untreated Eudragit powder. This suggests that, at 2.5% and 10% 463 hydrocortisone loading, the drug is soluble in the Eudragit L100 polymer matrix giving rise to a solid 464 solution. For 25% hydrocortisone-loaded microparticles, where a proportion of the drug was 465 incorporated in its crystalline form, a small endothermic peak at around 200˚C corresponding to 466 melting point depressed hydrocortisone crystals was observed. X-ray analysis of these samples 467 (Figure 7) supports the DSC data with no crystalline drug found at low loadings but excess drug (at 468 25% w/w loading) was present in the same crystalline form as the starting material. 469
However, for spray dried materials, hydrocortisone-loaded Eudragit L100 microparticles show an 470 endothermic shoulder which moves to a lower temperature as the drug loading increases ( Figure 6 ). 471
However, as the polymer also shows an endothermic peak in the same region, it was unclear 472 whether this thermal feature was due to the presence of drug crystals. From the X-ray diffraction 473 patterns of unprocessed drug and hydrocortisone-loaded microparticles, the intense crystalline 474 peaks at 14.5 and 17 degrees 2θ, observed for unprocessed hydrocortisone, were absent in the 475 diffractogram of drug-containing spray dried microparticles (Figure 7) . This suggests that the drug is 476 present in an amorphous form within the spray dried microparticles. The presence of amorphous 477 drug, coupled with the small size of spray dried microparticles may facilitate drug release and can 478 partly explain the relatively high burst release observed for this material (Figure 5, A) . However, the 479 fact that the drug is non-crystalline at 2.5% and 10% w/w within Eudragit L100 microparticles 480 produced from the oil-in-oil microencapsulation method suggests that this phenomenon is not solely 481 responsible for the non-controlled burst effect; a further potential mechanism is the relatively high 482 drug enrichment at the surface of the spray dried microparticles compared with the oil-in-oil 483 powders. 484
3.4.4
Drug distribution within the microparticles
485
In order to clarify whether release from the microparticles relates to the spatial distribution of the 486 drug within the polymer matrix, confocal Raman microscopy was used for depth profiling Eudragit 487 L100 microparticles [46] . As discussed above, the evaporation of ethanol during microencapsulation 488 can result in drug migration to the microparticle's surface resulting in surface drug enrichment which 489 can result in a higher or more rapid drug release. 490 Figure 8 shows the Raman spectra of hydrocortisone and Eudragit L100 powders used for 491 microparticle production. Hydrocortisone has characteristic Raman bands at 1643 and 1610 cm -1 492 which are consistent with C=C stretching modes at the 4-5 position [47, 48] (Figure 8 ). On the other 493 hand, Eudragit L100 shows distinctive Raman peaks at 1751 and 1451 cm -1 which are assigned to the 494 C=O stretching and -CH 2 -scissoring modes respectively [48] . The Raman spectrum of this polymer 495 also displays relatively strong peaks at 1205, 1120, 969 and 812 cm -1 which are associated with C-H 496 and C-C wagging vibrations [48] . 497
Insert Figure 8 498
Raman depth profiling of Eudragit L100 microparticles at 25% w/w drug-loading is shown in Figure 9 , 499 A (data not shown for 2.5% and 10% w/w drug-loading). Based on the linear relationship between 500 the intensity of the peak from the measured analyte and its concentration [49] , the depth profiles 501 were processed to acquire component graphs detailing the proportion of both hydrocortisone and 502
Eudragit L100 as a function of depth (Figure 9 , C, D and E). At 25% w/w drug-loading, the intensities 503 of the characteristic hydrocortisone peaks at 1643 and 1610 cm -1 were variable: they increased 504 dramatically at a depth of 12 µm then declined (Figure 9, A) . This high intensity region coincides with 505 the presence of a drug crystal inside the microparticle as illustrated in the SEM image of a 506 microtomed 25% w/w hydrocortisone-loaded particle where drug crystals can be seen both on the 507 surface and within the polymer matrix (Figure 9, B ). It should also be noted that this SEM image 508 supports tap density measurements obtained for the 25% w/w drug-loaded microparticles (Table 3) . 509
The considerably lower tap density measurement of these microparticles (Table 3) compared to 510 other powders containing lower amounts of drug is due to a higher level of intraparticulate voids. 511 SEM images of the internal structure of 2.5% and 10% w/w hydrocortisone-containing microparticles 512 showed no evidence of crystal inclusions. 513
Insert Figure 9 514
In the case of 2.5% and 10% w/w hydrocortisone-loading, the proportion of both hydrocortisone and 515 Eudragit L100 remained constant throughout the depth studied ( Figure 9 , D and E). Assuming that 516 these microparticles have a monodisperse size of about 30 µm (Figure 4) , these results show that the 517 concentration of hydrocortisone at the surface and the core (15.20 µm) is the same, i.e. the oil-in-oil 518 microencapsulation process did not result in drug enrichment on the surface. In contrast, with 25% 519 w/w hydrocortisone-loading, the proportion of hydrocortisone relative to Eudragit L100 varied 520 depending on the presence of drug crystals within the polymer matrix (Figure 9 . C). These results 521 support SEM images and XRPD/DSC data, with regions within the particle showing increased 522 intensities of hydrocortisone characteristic bands showing the presence of drug crystals. It should be 523 noted that the data presented in Figure 9 is representative of three different microparticles selected 524 randomly for each drug loading. Unfortunately, depth profiling of the spray dried microparticles for 525 comparative purposes was not possible due to their small particle size (size range 1-5 µm, Figure 2 ). 526
Since Raman depth profiling of the oil-in-oil microparticles demonstrated that, at 2.5% and 10% w/w 527 drug-loading, no differences in the spatial distribution of hydrocortisone existed within the polymer 528 matrix, variations in drug release at pH 7 can be solely due to differences in the polymer/drug ratio. 529
In other words, an increase in the proportion of Eudragit L100 relative to hydrocortisone, e.g. at 530 2.5% drug-loading, leads to a moderately slower drug release as a larger amount of polymer is 531 available to hinder drug diffusion. 532
Conclusion
533
Of the different microencapsulation techniques tested, spray drying and the oil-in-oil emulsification 534 method successfully formed microparticles with high levels of drug encapsulation. Scanning electron 535 microscopy and dissolution testing revealed that the microparticles prepared from the oil-in-oil 536 encapsulation method had more favourable morphological and release characteristics. In fact, the encapsulation of hydrocortisone at levels below its saturation solubility within Eudragit L100; 2.5 and 538 10% w/w, lead to negligible release at pH 5, a pH at which the polymer is not soluble, whereas 539 increasing the pH to 7 resulted in near instantaneous drug release. The spray dried powders, on the 540 other hand, showed high drug burst release at pH 5. These variations in drug release are partially 541 attributed to differences in microparticle formation. In contrast with the spray drying process, slow 542 solvent evaporation and droplet solidification during the oil-in-oil emulsification process allows 543 adequate time for drug and polymer redistribution which may result in denser microparticles and 544 better controlled release characteristics. Tap density measurements showed good correlation with 545 in-vitro drug release testing and SEM imaging, especially for the oil-in-oil produced microparticles, 546 with high density particles showing better controlled release properties. Thermal, X-ray and 547 confocal Raman analysis of the particles also demonstrates the importance of drug loading on 548 release properties; below the solubility limit, drug was homogeneously distributed and was non-549 crystalline whereas exceeding the solubility generated crystalline domains in oil-in-oil generated 550 materials with consequent burst release. Thus, both the manufacturing method (which influences 551 particle porosity and density) and drug:polymer compatibility and loading (which affect drug form 552 and distribution) are responsible for burst release seen from our particles. 553 654
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